This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of proven and probable IFIs
Timeframe: 90 days post-transplant
Incidence of proven and probable breakthrough IFI
Timeframe: While receiving rezafungin, voriconazole, or fluconazole